EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world-evidence (SIESTA-A study)

Ma Carmen Montero-Balosa, Juan A Limón-Mora, Ana Leal-Atienza, Beatriz García-Robredo, Pablo Sánchez-Villegas, Rebeca Isabel-Gómez, Ma José Aguado-Romeo, Luis Gabriel Luque Romero, Ma Teresa Molina-López

Frontiers in Pharmacology · 01.08.2025 · 16

DOI: 10.3389/fphar.2025.1548298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 01.08.2025. Verfasst von Ma Carmen Montero-Balosa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Primary Care Pharmacy, Aljarafe-Sevilla Norte District. Andalusian Health Service, Seville, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Pública Andaluza para La Gestión de la Investigación en Salud de Sevilla.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to evaluate the effectiveness and safety of direct oral anticoagulants (DOACs: dabigatran, rivaroxaban, apixaban and edoxaban) and warfarin versus acenocoumarol in patients with atrial fibrillation under real-world clinical practice conditions.

Methods

This was a retrospective, real-world data-based study. The data source was the Andalusian Population Health Database. The study covered the period from January 2012 to December 2020. Effectiveness outcomes were defined as the identification of a first occurrence of ischaemic or bleeding events, or all-cause mortality. The statistical analysis included crude incidence analysis, survival models: Kaplan-Meier curves, propensity score matched pairs analysis, Fine-Gray model, and Cox regression analysis adjusted for possible confounding.

Results

A total of 150,949 patients were included. The mean age of the cohort was 74 years (48.2% female). The mean follow-up time was 3.3 years. The combined effectiveness endpoint of ischaemic events (transient ischaemic attack, systemic embolism, pulmonary embolism, or ischaemic stroke) showed the following results compared to acenocoumarol: warfarin (RR:1.06; 95%CI 0.93–1.22); dabigatran (RR:1.17; 95%CI 1.02–1.33); rivaroxaban (RR:1.15; 95%CI 1.05–1.26); apixaban (RR: 0.96; 95%CI 0.87–1.07) and edoxaban (RR: 1.10; 95%CI 0.79–1.51). Compared to acenocoumarol, the risk of all-cause mortality was lower for dabigatran, rivaroxaban and apixaban (RR:0.77; 95%CI 0.72–0.82; RR:0.79; 95%CI 0.76–0.83; RR:0.85; 95%CI 0.81–0.89, respectively) and higher for warfarin (RR:1.12; 95%CI 1.05–1.20). An increased risk of gastrointestinal bleeding was observed with dabigatran (RR:1.36; 95%CI 1.09–1.70) and a lower risk with rivaroxaban (RR:0.84; 95%CI 0.72–0.98). All 4 DOACs showed a lower risk of intracranial bleeding compared to acenocoumarol. Warfarin carried a higher risk of both gastrointestinal bleeding (RR:1.64; 95%CI 1.31–2.06) and intracranial bleeding (RR:1.61; 95%CI 1.22–2.13) compared to acenocoumarol. An unadjusted analysis of matched groups in a multivariate Cox regression analysis yielded similar results for combined effectiveness and safety outcomes compared to acenocoumarol.

Conclusion

Although DOACs were clearly associated with a lower risk of intracranial bleeding compared to acenocoumarol, our data did not reveal a significant reduction in thromboembolic events. Warfarin was found to be both less effective and less safe than acenocoumarol.

Schlagwörter

Stichwörter der Autor:innen

effectivenesshealth outcomesoral anticoagulant agentsoral direct anticoagulantssafety

Autor:innen und Institutionen

  • Primary Care Pharmacy, Aljarafe-Sevilla Norte District. Andalusian Health Service, Seville, Spain.
  • Coordination of Management and Evaluation, Andalusian Health Service., Seville, Spain.
  • Andalusian Public Foundation for the Management of Health Research in Seville (FISEVI), Seville, Spain.
  • Primary Care Pharmacy, Seville District. Andalusian Health Service, Seville, Spain.
  • Andalusian School of Public Health, Granada, Spain.
  • Andalusian Health Technology Assessment Area, Progress and Health Foundation, Seville, Spain.

Förderung

  • Fundación Pública Andaluza para La Gestión de la Investigación en Salud de Sevilla

Zitieren

APA

Montero-Balosa, M. C., Limón-Mora, J. A., Leal-Atienza, A., García-Robredo, B., Sánchez-Villegas, P., Isabel-Gómez, R., Aguado-Romeo, M. J., Luque Romero, L. G., & Molina-López, M. T. (2025). Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world-evidence (SIESTA-A study). Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1548298

Vancouver

Montero-Balosa MC, Limón-Mora JA, Leal-Atienza A, García-Robredo B, Sánchez-Villegas P, Isabel-Gómez R, et al. Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world-evidence (SIESTA-A study). Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1548298

BibTeX
@article{MonteroBalosa2025,
  author = {Montero-Balosa, Ma Carmen and Limón-Mora, Juan A and Leal-Atienza, Ana and García-Robredo, Beatriz and Sánchez-Villegas, Pablo and Isabel-Gómez, Rebeca and Aguado-Romeo, Ma José and Luque Romero, Luis Gabriel and Molina-López, Ma Teresa},
  title = {Comparative clinical outcomes of acenocoumarol versus direct oral anticoagulants (DOACs) and warfarin in patients with atrial fibrillation: real-world-evidence (SIESTA-A study)},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1548298}
}
Kostenlos starten →